Infant Bacterial Therapeutics’ most advanced clinical program is the IBP-9414 project developing a preventive treatment against necrotizing enterocolitis (NEC).


  • The phase II safety and tolerability study in premature infants started in 2016
  • The active bacteria used in IBP-9414 is known to be anti-inflammatory, anti-pathogenic and beneficial to gut motility
  •  IBP-9414 contains a co-evolved human bacterial strain derived from human breast milk
  • IBP-9414 is formulated with close consideration of age-appropriateness of the vulnerable target population of preterm infants
  • IBP-9414 has been granted Orphan Drug Designation for the prevention of NEC by the FDA and by the European Commission
  • IBP-9414 has been granted Rare Pediatric Disease Designation for the prevention of NEC.


IBT is further pursuing a second rare disease programme IBP-1016 for the unmet medical need gastroschisis, a severe disease in infants.